IRWD Share Price

Open 17.05 Change Price %
High 17.26 1 Day 0.06 0.35
Low 16.95 1 Week 0.10 0.59
Close 17.10 1 Month -1.03 -5.68
Volume 642452 1 Year 2.49 17.04
52 Week High 19.94
52 Week Low 12.48
IRWD Important Levels
Resistance 2 17.39
Resistance 1 17.27
Pivot 17.10
Support 1 16.93
Support 2 16.81
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
DCTH 0.14 -6.67%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
SCHS 0.05 66.67%
CPSL 0.14 55.56%
LOCM 0.09 50.00%
HAUP 0.10 42.86%
SYMX 0.50 38.89%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
OPNT 11.40 24.73%
IFON 0.61 24.49%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
DCIX 0.19 -58.70%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)

IRWD Technical Analysis 2
As on 26th Jul 2017 IRWD Share Price closed @ 17.10 and we RECOMMEND Buy for LONG-TERM with Stoploss of 16.20 & Strong Sell for SHORT-TERM with Stoploss of 18.27 we also expect STOCK to react on Following IMPORTANT LEVELS.
IRWD Target for July
1st Target up-side 20.31
2nd Target up-side 21.31
3rd Target up-side 22.31
1st Target down-side 17.45
2nd Target down-side 16.45
3rd Target down-side 15.45
IRWD Other Details
Segment EQ
Market Capital 1211006720.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ironwoodpharma.com
IRWD Address
IRWD
301 Binney Street
Cambridge, MA 02142
United States
Phone: 617-621-7722
Fax: 617-494-0480
IRWD Latest News
Interactive Technical Analysis Chart Ironwood Pharmaceuticals, Inc. ( IRWD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ironwood Pharmaceuticals, Inc.
IRWD Business Profile
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines. The Company is engaged in the area of guanylate cyclase type-C (GC-C), agonists and in the science and treatment of gastrointestinal diseases. Its two GC-C agonists are linaclotide and IW-9179.